Tag: BARDA
Vaxxas secures $2M grant from BARDA to develop needle-free mRNA vaccines
Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize.
SAB Biotherapeutics awarded $57.5 to manufacture its therapeutic candidate for COVID-19
Clinical stage biopharma company SAB Biotherapeutics has been awarded $57.5 million from BARDA and the US Department of Defence for the manufacturing of SAB-185,...
Featured Article
GridBeyond highlights role of technology in navigating energy market swings
Energy price volatility continues to pose challenges for manufacturers and other energy-intensive industries, particularly as electricity markets experience more frequent and unpredictable price swings.
